Ethical considerations are paramount in neonatal trials. Adaptive designs can minimize risks to neonates by potentially shortening the trial duration and reducing the exposure to less effective treatments. Moreover, continuous monitoring and adjustments based on interim results ensure that the study remains aligned with ethical standards. However, it is crucial to pre-specify the rules for adaptations to prevent any bias or manipulation of the trial outcomes.
